Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Novozymes Biopharma Announces Collaboration with Almac

Published: Tuesday, October 22, 2013
Last Updated: Tuesday, October 22, 2013
Bookmark and Share
Combined service offers drug development companies efficiencies in time and resource.

Novozymes Biopharma has announced its new collaboration with Almac, to provide a combined service for drug development applications in the field of drug targeting and pharmacokinetic improvements.

The collaboration will allow clients to utilize Almac’s world-class manufacturing assets and protein conjugation capability to link Novozymes’ Recombumin® Flex technology successfully to their peptide and small molecule drugs.

This subsequently improves the pharmacokinetics and has already been shown to improve drug targeting in oncology and rheumatoid arthritis. Collaborations with commercial partners have already begun and will continue to expand in early 2014.

Novozymes and Almac have a solid history of cooperation in peptide and small molecule conjugation projects. The formalization of this collaboration offers drug developers the immediate benefit of continuity of service provision through the stages of clinical development -delivering efficiencies in time and internal resource, whilst increasing the chances of clinical success.

Clients will also benefit from extensive experience in product and service provision to the pharmaceutical industry with access to a comprehensive level of both technical and regulatory support.

Novozymes’ Recombumin® Flex technology will be the focal point of this collaboration. Novozymes has modified the amino acid sequence of human albumin to increase its receptor affinity, providing novel properties including improved half-life extension and drug targeting.

This technology naturally complements Almac’s expertise in peptide and small molecule manufacturing, and can also be allied to its world-class protein conjugation technology offerings. As a result, clients will be able to successfully use Almac’s technology to link Recombumin® Flex to their drug products as part of one contract service offering.

“By working alongside Almac, we are confident that we will be able to create more opportunities for developers seeking to benefit from the Recombumin® Flex technology,” stated Dermot Pearson, Marketing Director at Novozymes Biopharma. “the advantage of working with two companies well versed in providing products and services to the pharmaceutical industry is that customers gain the assurance that their needs will be provided for, not just in the short term, but right through to commercial supply.”

Denis Geffroy, VP Business Development for Almac stated: “This alliance has clear benefits for companies involved in both drug development and delivery technologies: a complete service can be recommended utilizing the core expertise of both parties at an early stage of clinical development, thus significantly enhancing the success of drug development programmes.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Almac Group Launches US Serialisation Solution
Company has announced an expansion to its serialisation capabilities to include its US commercial packaging facility in partnership with Optel Vision.
Thursday, May 12, 2016
Almac Group Addresses Industry Demand For Multiparticulate Drug Products
In response to increasing client demand for multiparticulate drug delivery systems, Almac Group is providing fluid-bed processing and encapsulation services to its global partners from its UK development and commercial manufacturing facilities.
Monday, October 12, 2015
Almac Addresses Industry Demand for Multiparticulate Drug Products
Company is providing scalable fluid bed and encapsulation technologies to its global partners.
Friday, October 09, 2015
Almac Group Expands Asia Pacific Presence
Company opens new regional headquarters and clinical trial supply facility in Singapore.
Thursday, July 16, 2015
Almac Expands US & UK Commercial Facilities
Investments of over $20m enhance Almac’s commercial facilities on both sides of the Atlantic.
Tuesday, October 22, 2013
Almac Announces Further Expansion and 229 New Jobs
Dual expansion with completion of a new non-GMP drug development facility.
Monday, June 17, 2013
Almac Launches US Commercial Packaging Operations in Audubon
Company also announces launch of new client partnership.
Monday, May 20, 2013
Almac Receives FDA Inspection Approval
Successful inspection of analytical facilities at Almac’s Craigavon Headquarters, Northern Ireland from the US FDA.
Thursday, February 21, 2013
Almac Doubles Drug Product Development Capacity with a New Non-GMP Facility
New facility offers clients greater flexibility and speed in formulation and process development.
Tuesday, January 15, 2013
Almac and TTP Labtech form Alliance in Fluorescence Lifetime Technology
This will give customers of either party access to a broad range of biological applications coupled with the next generation of microplate reader technology.
Tuesday, January 08, 2013
Charlie Morris Appointed to Almac’s Clinical Technologies Executive Team
Mr. Morris joins Almac as Vice President of new products and services.
Thursday, December 13, 2012
Almac Concludes Commercial API Manufacturing Facility Expansion Plans
Almac’s expansion is near completion and will be operational by the end of the year.
Tuesday, October 09, 2012
Almac Expands UK Commercial Capacity
Acquisition of new Noack N 623 blister packaging line from Romaco.
Friday, October 05, 2012
Almac Installs Uhlmann Blister Line in New US Commercial Packaging Facility
Acquisition of a high-speed blister line in Audubon, PA.
Monday, July 02, 2012
Almac Introduces QP Facilitation Programme for Conducting Trials in the European Union
Programme vastly simplifies and expedites the QP release process.
Thursday, June 14, 2012
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
New Medication Shows Promise Against Liver Fibrosis in Animal Studies
Liver fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.
Raw Eggs Deemed Safe to Eat
A report published today by the Advisory Committee on the Microbiological Safety of Food (ACMSF) into egg safety has shown a major reduction in the risk from salmonella in UK eggs.
Monitoring TTX Toxin in Shellfish
In a number of small studies, mussels and oysters from the eastern and northern part of the Oosterschelde in Holland were found to contain tetrodotoxin (TTX).
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Detecting Alzheimer's with Smell Test
Odour identification test may offer low-cost alternative for predicting cognitive decline and detecting early-stage Alzheimer’s disease.
Antibody Drug Shows Promise in HIV Treatment
Researchers are a step closer to an alternative HIV treatment that has the potential for lasting effects and less frequent dosing.
Testing Nanoparticle Drug Delivery in Dogs
Scientists have tested a nanoparticle drug delivery against bone cancer in dogs with promising results.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!